Christopher DeRespino - 24 Jun 2021 Form 3 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
Acting Chief Financial Officer and Chief Business Officer
Signature
Christopher DeRespino, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
ADVM
Transactions as of
24 Jun 2021
Net transactions value
$0
Form type
3
Filing time
29 Jun 2021, 18:53:32 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ADVM Stock Option (Right to Buy) 24 Jun 2021 Common Stock 425,000 $12.84 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 18, 2021 (the "Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Remarks:

Acting Chief Financial Officer and Chief Business Officer